Top videos
URBN Dental is here not only to take care of your tooth decay and prevent gingivitis, but also to give you the best at home dental care instructions as well. Do you find brushing your teeth confusing, or are you unsure whether or not you are brushing correctly? The golden standard when it comes to brushing teeth is brushing twice a day for two minute sessions each. You can break down the mouth into four quadrants: upper right, upper left, lower left, and lower right. By doing this, it will be easier for you to brush for thirty seconds in each area and focus on the correct movement instead of location. It is very important to angle the toothbrush at a forty five degree angle to the tooth and gums while using circular motions to remove food debris and plaque. When it comes to your front teeth, using the brush in a vertical position and combining it with circular motions is effective. Using the dental techniques will ensure healthier teeth that are cavity free and less bleeding gums.
Current treatment is a combination of pegylated interferon-alpha-2a or pegylated interferon-alpha-2b (brand names Pegasys or PEG-Intron) and the antiviral drug ribavirin for a period of 24 or 48 weeks, depending on hepatitis C virus genotype. In a large multicenter randomized control study among genotype 2 or 3 infected patients (NORDymanIC),[35] patients achieving HCV RNA below 1000 IU/mL by day 7 who were treated for 12 weeks demonstrated similar cure rates as those treated for 24 weeks.[36][37]
Pegylated interferon-alpha-2a plus ribavirin may increase sustained virological response among patients with chronic hepatitis C as compared to pegylated interferon-alpha-2b plus ribavirin according to a systematic review of randomized controlled trials .[38] The relative benefit increase was 14.6%. For patients at similar risk to those in this study (41.0% had sustained virological response when not treated with pegylated interferon alpha 2a plus ribavirin), this leads to an absolute benefit increase of 6%. About 16.7 patients must be treated for one to benefit (number needed to treat = 16.7; click here [39] to adjust these results for patients at higher or lower risk of sustained virological response). However, this study's results may be biased due to uncertain temporality of association, selective dose response.
Treatment is generally recommended for patients with proven hepatitis C virus infection and persistently abnormal liver function tests.
Treatment during the acute infection phase has much higher success rates (greater than 90%) with a shorter duration of treatment; however, this must be balanced against the 15-40% chance of spontaneous clearance without treatment (see Acute Hepatitis C section above).
Those with low initial viral loads respond much better to treatment than those with higher viral loads (greater than 400,000 IU/mL). Current combination therapy is usually supervised by physicians in the fields of gastroenterology, hepatology or infectious disease.
The treatment may be physically demanding, particularly for those with a prior history of drug or alcohol abuse. It can qualify for temporary disability in some cases. A substantial proportion of patients will experience a panoply of side effects ranging from a 'flu-like' syndrome (the most common, experienced for a few days after the weekly injection of interferon) to severe adverse events including anemia, cardiovascular events and psychiatric problems such as suicide or suicidal ideation. The latter are exacerbated by the general physiological stress experienced by the patient.
Multiple endocrine neoplasia type 2 (MEN2) is a hereditary condition associated with three primary types of tumors: medullary thyroid cancer, parathyroid tumors, and pheochromocytoma. MEN2 is classified into three subtypes based on clinical features. MEN2A, which affects 60% to 90% of MEN2 families Medullary thyroid cancer: 98% to 100% with MEN2A are affected Pheochromocytoma, a typically benign (noncancerous) tumor of the adrenal glands: 50% with MEN2A affected Parathyroid adenoma (benign tumor) or hyperplasia, meaning increased size, of the parathyroid gland: 5% to 10% with MEN2A affected MEN2B, which affects 5% of MEN2 families Medullary thyroid cancer: 98% to 100% with MEN2B affected Pheochromocytoma: 50% with MEN2B affected Mucosal neuromas, which is a benign tumor of nerve tissue on the tongue, lips and throughout the gastrointestinal tract: 95% to 98% affected Digestive problems caused by disordered nerves in the gastrointestinal tract: 75% to 90% affected Muscle, joint, and spinal problems: 95% affected Typical facial features, including swollen lips and thick eyelids: 75% to 90% affected Familial medullary thyroid cancer (FMTC), which affects 5% to 35% of MEN2 families Medullary thyroid carcinoma only Sources: Gagel RF, Marx SJ. “Multiple endocrine neoplasia.” Williams Textbook of Endocrinology, Chapter 40, 11th ed., Philadelphia, 2008, and Eng C, Clayton D, et al. Grubbs EG, Gagel RF. My, How Things Have Changed in Multiple Endocrine Neoplasia Type 2A! J Clin Endocrinol Metab 100(7):2532-5, 7/2015. PMID: 26151398. What causes MEN2? MEN2 is a genetic condition. This means that the cancer risk and other features of MEN2 can be passed from generation to generation in a family. The gene associated with MEN2 is called RET. A mutation (alteration) in the RET gene gives a person an increased risk of developing medullary thyroid cancer and other tumors associated with MEN2.
Hypothyroidism during pregnancy is treated with synthetic thyroid hormone, thyroxine (T4). Postpartum thyroiditis—inflammation of the thyroid gland—causes a brief period of hyperthyroidism, often followed by hypothyroidism that usually goes away within a year. Sometimes the hypothyroidism is permanent.
urgical management of proximal humerus fractures may be categorized either according to fracture type (eg, Neer type, anatomic type, greater tuberosity, surgical neck, anatomic neck, articular surface, lesser tuberosity fragments) or according to method of fixation (eg, closed reduction with no fixation, percutaneous fixation, open reduction with internal fixation [ORIF], humeral head replacement associated with tuberosity fixation
PURPOSE: Laparoscopic partial nephrectomy (LPN) is an alternative modality of treatment for small sized renal cell carcinoma. Robot assisted laparoscopic partial nephrectomy (RLPN) has also been performed with an advantage in repairing resected surface after tumor resection. We compare the periopera...
tive data of patients treated with laparoscopic partial nephrectomy with those of RLPN undertaken patients. MATERIAL AND METHOD: From September 2006 to April 2008, 22 patients were treated with LPN and 22 were RLPN. 3 arms were used for RLPN; camera was inserted through the 12mm, umbilical trocar port. The laparoscopic Bulldog clamp was used for the clamping of renal hilum. We retrospectively compared each group about tumor size, operation time, estimated blood loss, warm ischemic time and hospital stay. RESULT: Operation time of LPN was shorter than that of RLPN (p=0.033). Tumor size, estimated blood loss and hospital stay was not significant different in each group. No case had conversion to open surgery. 1 patient of RLPN group, however, had conversion to radical nephrectomy due to severe bleeding. CONCLUSION: RLPN was safe and feasible in small sized renal cell carcinoma. Warm ischemic time was reasonable and morbidity associated with RLPN was also low. RLPN LPN p-value Tumor Size (cm) 2.5 2.1 0.605 Op time (min) 169.3 140.8 0.033 EBL (ml) 243.2 213.2 0.878 Warm Ischemic Time (min) 29.2 26.4 0.237 Transfusion (%) 4.5 4.5 0.756 Hospital stay (day) 4.4 5.5 0.053